PKU patients have elevated phenylalanine levels which can result in neurological impairment. Here the authors utilize biosensor-based ultra-high-throughput screening to optimize PAL activity in a synthetic biotic platform for improved in vivo performance.
- Kristin J. Adolfsen
- Isolde Callihan
- Vincent M. Isabella
